Navigation Links
Study shows drug combination improves outcome for advanced non-small cell lung cancer
Date:5/30/2009

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III "ATLAS" trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting.

The goal of the study was to determine whether adding erlotinib (Tarceva), a targeted agent, to maintenance therapy with bevacizumab (Avastin), an agent commonly used as a component of treatment for advanced NSCLC would delay disease progression. Maintenance therapy involves using one or more agents of a chemotherapy regimen, but not the entire regimen, to delay disease progression and possibly improve survival after patients have previously received stronger standard chemotherapy, which can have significant side effects.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," said Dr. Miller, a thoracic oncologist at MSKCC and one of the study's lead authors. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research," Dr. Miller added.

In total, 768 patients were randomized to receive bevacizumab plus erlotinib or bevacizumab plus placebo after initial cytotoxic chemotherapy with bevacizumab. There was a 29 percent reduction in the risk of progression for those patients treated with erlotinib, and the median progression-free survival (the time it took for the cancer to get worse) was 4.8 months for the combination versus 3.7 months for the bevacizumab-placebo group. Because a statistically significant improvement in efficacy was found in the erlotinib group, the trial was stopped early. The combination was also found to be safe and well tolerated.

Bevacizumab and erlotinib are classified as targeted therapies agents that block tumor growth by interfering with specific molecules critical to the survival of cancer cells. Individually, both drugs have shown promise in previous studies in the treatment of NSCLC.

According to the National Cancer Institute, in 2008 the estimated number of new lung cancer cases (non-small cell and small cell combined) was 215,000 and the number of deaths was 161,840. Non-small cell lung cancer is the most common among all lung cancers and is usually associated with a history of tobacco use.


'/>"/>

Contact: Courtney DeNicola
denicolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology: